Colonized With Candida auris, Now Septic — Which Drug Covers the Blood Cultures That Aren't Back Yet
A single patient, already known to carry the outbreak organism before she got sick. The disagreement is whether the unit's own recent numbers or her own three-week-old culture is the better guide, with no time to wait for both.
M.K., a 71-year-old woman, has been ventilator-dependent in this long-term acute care unit for eleven weeks, the tail end of a surgical ICU course that began with a bowel perforation and has not let her fully surface since. Nursing home admission screening three weeks ago found Candida auris colonizing her nares and axillae, part of a facility-wide outbreak the unit has been managing under enhanced isolation and surveillance protocols. She was previously living independently and managing well before the surgical emergency that started this admission — the baseline this whole course has been measured against. This morning she spiked to 39.4°C, her blood pressure dropped to 78/44 despite her usual pressor requirement, and blood cultures were drawn from both her central line and peripherally before broad empiric coverage was started, well before speciation or susceptibility could return.
The unit's own recent isolate data complicates what would otherwise be a straightforward empiric choice. C. auris nationally remains predominantly echinocandin-susceptible even where fluconazole resistance runs near-universal, which is why guidelines still name echinocandins first-line even in outbreak settings — but this unit's isolates over the past six weeks have shown a rising minority with reduced echinocandin susceptibility as well, a local trend that doesn't yet describe the national picture cited in that guidance. What the unit's aggregate trend can't tell anyone is what her own organism will do, and her chart already holds an answer to a narrower, more useful question: her admission colonization swab, cultured and speciated three weeks ago, tested fully echinocandin-susceptible — a real result about her own organism, drawn before this outbreak's more recent isolates started showing the shift the unit is now tracking, and not yet known to have changed in the interval since. Whether a colonizing strain and whatever is now growing in her blood are still the same isolate is itself an assumption the team is making rather than a fact already confirmed, and everyone in the room knows that going in.
At the bedside, before speciation is back
Both CDC and IDSA guidance keep echinocandins as first-line empiric therapy even in documented outbreak settings, because most isolates nationally remain echinocandin-susceptible, including a real share of the pan-resistant-labeled outbreaks reported elsewhere. I don't want us defaulting to amphotericin B on population-level alarm when the drug class's national reliability hasn't actually changed.
The national number isn't what I'm worried about — it's this unit's own isolates. We've had a rising minority of reduced-echinocandin-susceptibility strains here specifically over the past six weeks, and she's hypotensive right now. If we guess wrong for the 48 hours it takes speciation to come back, that's not a stewardship cost, it's a mortality one.
"Most isolates nationally remain susceptible" is true and also not the number that describes our own unit's recent pattern, which is the more relevant one for her specifically.
Neither the national rate nor our unit's aggregate is actually the best available evidence here — her own colonizing isolate, cultured three weeks ago at admission screening, tested fully echinocandin-susceptible. That's a real data point about her, not a population estimate. I'd start micafungin guided by that result, with a firm agreement to reassess immediately once today's blood culture speciation and susceptibility return, since colonizing and infecting isolates can genuinely diverge and her own prior result isn't a guarantee.
Agreed: micafungin started empirically based on her own three-week-old isolate data, with same-day escalation to liposomal amphotericin B if today's blood culture speciation shows reduced echinocandin susceptibility rather than waiting for a clinical decline to confirm the switch is needed.
Not agreed, and flagged beyond this one patient: the stewardship pharmacist and ID physician both want the unit's surveillance protocol updated to speciate and re-test colonizing isolates on a standing schedule rather than treating a single admission swab as valid indefinitely, since colonizing and infecting isolates in this outbreak can diverge — a unit-level question the critical care physician agrees needs answering, but not one this bedside decision resolves today.